This webinar has been supported and funded by Menarini Diagnostics company. All opinions expressed are those of the speakers involved and not necessarily representative of the views of Menarini or EMJ.
Join Fred Witjes and Param Mariappan as they present new scientific evidence on urine bladder cancer biomarkers that delves into the expected benefits of adopting bladder cancer biomarkers in clinical practice and discuss the impact on clinical practice.
Timestamps:
- 00:00 – Introduction
- 1:17 – Current limitations in existing diagnostic methods of non-muscle invasive bladder cancer
- 3:02 – Are urinary markers the solution?
- 4:58 – Current markers in the market
- 13:04 – Combining Bladder EpiCheck & PDD in real-world HR-NMIBC surveillance
- 14.24 – Diagnostic limitations of current methods
- 15:46 – How do we handle anticipatory positives?
Speaker Discussion
- 23:00 – Speaker Discussion
Speakers:
Fred Witjes1,2
Param Mariappan3
1. Director, Edinburgh Bladder Cancer Surgery (EBCS), Western General Hospital, Edinburgh, UK
2. Consultant Urological Surgeon, The University of Edinburgh, UK
3. Radboud University Nijmegen, the Netherlands
Disclosure: Mariappan has received honoraria and advisory/sponsorships from Baxter, BMS, Coloplast, Ethicon, Janssen, Medac Pharma, Pfizer, Photocure, and Storz; designed & developed Scot BC Quality OPS; is an EAU Guideline panels member for NMIBC, UTUC, and MIBC; is part of the Core Committee for the International Bladder Cancer Group (IBCG); is TSC for RESECT and YORKSURe; and Medical Advisor for the Fight Bladder Cancer charity. Witjes is an advisor/lecturer for BMS, Medac, Thermosome, CAPS, Combat, JeMedis, Photocure, Astellas, MEL, Sanofi Pasteur Canada, Nucleix Israel, and Spectrum Pharma; and has received financial support from Ipsen.
